원문정보
초록
영어
The pharmaceutical industry has traditionally focused on developing therapies using synthetic small molecules. However many environments such as a generic threat and an R&D productivity crisis have changed the dynamics of the pharmaceutical industry. The major players in the
industry have recognized the high potential of biological therapies. In near future, it is expected to drive a significant change in their R&D portfolios. Biologics are expected to account for the majority of the total growth in the pharmaceutical sector. In 2014, seven among the top 10 products by sales will be the Biologics. One of the major fields for application of biological products is the autoimmune disease such as a Rheumatoid arthritis. The market size of the TNF blockade will be expended to 20 billion dollars. The final goal of our program is to commercialize the biologics as a best in class drug and/or as a first in class drug for the treatment of autoimmune diseases.